121 related articles for article (PubMed ID: 37869881)
1. Effect of Dapagliflozin on 6-Minute Walk Distance in Heart Failure With Preserved Ejection Fraction: PRESERVED-HF.
Lewis GD; Gosch K; Cohen LP; Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Kosiborod MN; Sauer AJ
Circ Heart Fail; 2023 Nov; 16(11):e010633. PubMed ID: 37869881
[TBL] [Abstract][Full Text] [Related]
2. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
3. Dapagliflozin Improves Heart Failure Symptoms and Physical Limitations Across the Full Range of Ejection Fraction: Pooled Patient-Level Analysis From DEFINE-HF and PRESERVED-HF Trials.
Nassif ME; Windsor SL; Gosch K; Borlaug BA; Husain M; Inzucchi SE; Kitzman DW; McGuire DK; Pitt B; Scirica BM; Shah SJ; Umpierrez G; Austin BA; Lamba S; Khumri T; Sharma K; Kosiborod MN
Circ Heart Fail; 2023 Jul; 16(7):e009837. PubMed ID: 37203441
[TBL] [Abstract][Full Text] [Related]
4. Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial.
Nassif ME; Windsor SL; Tang F; Khariton Y; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Austin B; Drazner MH; Fong MW; Givertz MM; Gordon RA; Jermyn R; Katz SD; Lamba S; Lanfear DE; LaRue SJ; Lindenfeld J; Malone M; Margulies K; Mentz RJ; Mutharasan RK; Pursley M; Umpierrez G; Kosiborod M
Circulation; 2019 Oct; 140(18):1463-1476. PubMed ID: 31524498
[TBL] [Abstract][Full Text] [Related]
5. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial.
Kosiborod MN; Jhund PS; Docherty KF; Diez M; Petrie MC; Verma S; Nicolau JC; Merkely B; Kitakaze M; DeMets DL; Inzucchi SE; Køber L; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Bengtsson O; Lindholm D; Niklasson A; Sjöstrand M; Langkilde AM; McMurray JJV
Circulation; 2020 Jan; 141(2):90-99. PubMed ID: 31736335
[TBL] [Abstract][Full Text] [Related]
6. The SGLT2 inhibitor dapagliflozin in heart failure with preserved ejection fraction: a multicenter randomized trial.
Nassif ME; Windsor SL; Borlaug BA; Kitzman DW; Shah SJ; Tang F; Khariton Y; Malik AO; Khumri T; Umpierrez G; Lamba S; Sharma K; Khan SS; Chandra L; Gordon RA; Ryan JJ; Chaudhry SP; Joseph SM; Chow CH; Kanwar MK; Pursley M; Siraj ES; Lewis GD; Clemson BS; Fong M; Kosiborod MN
Nat Med; 2021 Nov; 27(11):1954-1960. PubMed ID: 34711976
[TBL] [Abstract][Full Text] [Related]
7. Targeted Metabolomic Profiling of Dapagliflozin in Heart Failure With Preserved Ejection Fraction: The PRESERVED-HF Trial.
Selvaraj S; Patel S; Sauer AJ; McGarrah RW; Jones P; Kwee LC; Windsor SL; Ilkayeva O; Muehlbauer MJ; Newgard CB; Borlaug BA; Kitzman DW; Shah SJ; Shah SH; Kosiborod MN;
JACC Heart Fail; 2024 Jun; 12(6):999-1011. PubMed ID: 38639697
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial.
Butt JH; Adamson C; Docherty KF; de Boer RA; Petrie MC; Inzucchi SE; Kosiborod MN; Maria Langkilde A; Lindholm D; Martinez FA; Bengtsson O; Schou M; O'Meara E; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Jhund PS; McMurray JJV; Køber L
Circ Heart Fail; 2021 Dec; 14(12):e008837. PubMed ID: 34802253
[TBL] [Abstract][Full Text] [Related]
9. Sex Differences in Characteristics, Outcomes, and Treatment Response With Dapagliflozin Across the Range of Ejection Fraction in Patients With Heart Failure: Insights From DAPA-HF and DELIVER.
Wang X; Vaduganathan M; Claggett BL; Hegde SM; Pabon M; Kulac IJ; Vardeny O; O'Meara E; Zieroth S; Katova T; McGrath MM; Pouleur AC; Jhund PS; Desai AS; Inzucchi SE; Kosiborod MN; de Boer RA; Kober L; Sabatine MS; Martinez FA; Ponikowski P; Shah SJ; Hernandez AF; Langkilde AM; McMurray JJV; Solomon SD; Lam CSP
Circulation; 2023 Feb; 147(8):624-634. PubMed ID: 36342789
[TBL] [Abstract][Full Text] [Related]
10. Effect of Dapagliflozin on Health Status in Patients With Preserved or Mildly Reduced Ejection Fraction.
Kosiborod MN; Bhatt AS; Claggett BL; Vaduganathan M; Kulac IJ; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Vardeny O; Lindholm D; Wilderäng U; Bengtsson O; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2023 Feb; 81(5):460-473. PubMed ID: 36526515
[TBL] [Abstract][Full Text] [Related]
11. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial.
Mc Causland FR; Claggett BL; Vaduganathan M; Desai A; Jhund P; Vardeny O; Fang JC; de Boer RA; Docherty KF; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Saraiva JFK; McGrath MM; Shah SJ; Verma S; Langkilde AM; Petersson M; McMurray JJV; Solomon SD
JAMA Cardiol; 2024 Feb; 9(2):144-152. PubMed ID: 37952176
[TBL] [Abstract][Full Text] [Related]
12. Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF.
Adamson C; Docherty KF; Heerspink HJL; de Boer RA; Damman K; Inzucchi SE; Køber L; Kosiborod MN; Martinez FA; Petrie MC; Ponikowski P; Sabatine MS; Schou M; Solomon SD; Verma S; Bengtsson O; Langkilde AM; Sjöstrand M; Vaduganathan M; Jhund PS; McMurray JJV
Circulation; 2022 Aug; 146(6):438-449. PubMed ID: 35442064
[TBL] [Abstract][Full Text] [Related]
13. Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial.
Berg DD; Docherty KF; Sattar N; Jarolim P; Welsh P; Jhund PS; Anand IS; Chopra V; de Boer RA; Kosiborod MN; Nicolau JC; O'Meara E; Schou M; Hammarstedt A; Langkilde AM; Lindholm D; Sjöstrand M; McMurray JJV; Sabatine MS; Morrow DA
Circulation; 2022 Jan; 145(3):158-169. PubMed ID: 34743554
[TBL] [Abstract][Full Text] [Related]
14. Endothelin-1, Outcomes in Patients With Heart Failure and Reduced Ejection Fraction, and Effects of Dapagliflozin: Findings From DAPA-HF.
Yeoh SE; Docherty KF; Campbell RT; Jhund PS; Hammarstedt A; Heerspink HJL; Jarolim P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Solomon SD; Sjöstrand M; Bengtsson O; Greasley PJ; Sattar N; Welsh P; Sabatine MS; Morrow DA; McMurray JJV
Circulation; 2023 May; 147(22):1670-1683. PubMed ID: 37039015
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Dapagliflozin According to Heart Rate: A Patient-Level Pooled Analysis of DAPA-HF and DELIVER.
Kondo T; Butt JH; Curtain JP; Jhund PS; Docherty KF; Claggett BL; Vaduganathan M; Bachus E; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Solomon SD; McMurray JJV
Circ Heart Fail; 2023 Dec; 16(12):e010898. PubMed ID: 37886880
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Dapagliflozin in Men and Women With Heart Failure With Reduced Ejection Fraction: A Prespecified Analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure Trial.
Butt JH; Docherty KF; Petrie MC; Schou M; Kosiborod MN; O'Meara E; Katova T; Ljungman CEA; Diez M; Ogunniyi MO; Langkilde AM; Sjöstrand M; Lindholm D; Bengtsson O; Martinez FA; Ponikowski P; Sabatine MS; Solomon SD; Jhund PS; McMurray JJV; Køber L
JAMA Cardiol; 2021 Jun; 6(6):678-689. PubMed ID: 33787831
[TBL] [Abstract][Full Text] [Related]
17. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
[TBL] [Abstract][Full Text] [Related]
18. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
Selvaraj S; Fu Z; Jones P; Kwee LC; Windsor SL; Ilkayeva O; Newgard CB; Margulies KB; Husain M; Inzucchi SE; McGuire DK; Pitt B; Scirica BM; Lanfear DE; Nassif ME; Javaheri A; Mentz RJ; Kosiborod MN; Shah SH;
Circulation; 2022 Sep; 146(11):808-818. PubMed ID: 35603596
[TBL] [Abstract][Full Text] [Related]
19. Effect of dapagliflozin on health status and quality of life across the spectrum of ejection fraction: Participant-level pooled analysis from the DAPA-HF and DELIVER trials.
Bhatt AS; Kosiborod MN; Vaduganathan M; Claggett BL; Miao ZM; Kulac IJ; Lam CSP; Hernandez AF; Martinez F; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2023 Jul; 25(7):981-988. PubMed ID: 37211977
[TBL] [Abstract][Full Text] [Related]
20. Effects of dapagliflozin and empagliflozin on 6-min walk distance in heart failure with preserved and reduced ejection fraction: A systematic review and meta-analysis of randomized controlled trials involving 2624 patients.
Tanashat M; Manasrah A; Abouzid M
Eur J Clin Pharmacol; 2024 Jul; 80(7):951-963. PubMed ID: 38498097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
